Novo Nordisk has entered a multiyear collaboration with Replicate Bioscience to harness self-replicating RNA (srRNA) technology for developing therapeutics addressing obesity, type 2 diabetes, and other cardiometabolic diseases. The partnership, valued at up to $550 million contingent on milestones plus royalties, grants Novo Nordisk exclusive global licenses to Replicate’s srRNA platform. SrRNA therapies enable prolonged and tunable protein expression, offering advantages over traditional mRNA modalities. This alliance complements Novo Nordisk’s ongoing expansion of its metabolic disease pipeline, following recent deals with other modality-focused biotech startups.